Abstract
BackgroundAutoimmune diseases (ADs) affect more than 24 million people in the United States. As patients with ADs are excluded from clinical trials of immune checkpoint inhibitors (ICI), management of AD...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
